Missing Voices in Diabetes Drug Trials

Recent research examined who gets tested with new diabetes medicines that also help the heart. The study looked at large phase three and four trials of SGLT‑2 inhibitors, drugs that lower blood sugar by making the kidneys excrete more glucose. These medicines have shown promise for people with type 2 diabetes and heart failure, but it was unclear whether the trial groups truly reflect all patients who might use them. The investigators searched dozens of studies and found that certain groups were under‑represented. Older adults, people with lower incomes, and some racial or ethnic minorities did not appear in the trials at the same rate as they do in real‑world populations. Women were also less common than expected, especially those who are pregnant or have other health conditions that might affect treatment.Because the trials did not include enough people from these groups, it is hard to know if the drugs work as well for them or if they carry extra risks. For example, kidney function varies with age and ethnicity; a medicine that is safe for one group could be less so for another. The lack of diversity also limits doctors’ ability to predict how the drugs will perform in everyday practice. The authors suggest that future studies should make a concerted effort to recruit a broader mix of participants. Regulatory agencies and pharmaceutical companies could set targets for inclusion, similar to how they now require women in many drug trials. Better representation would give patients and clinicians more reliable information about benefits, side effects, and long‑term outcomes. This analysis highlights a gap that matters for patient safety. When trials mirror the real world, medicine can be tailored more accurately to those who need it most.